Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Vilazodone(click to collapse)
1/4 selected
Vilazodone
Viibryd
Serotonin Partial Agonist Reuptake Inhibitor
FDA-approved indications
- Major depressive disorder (adults)
Off-label uses
- Generalized anxiety disorder
- OCD
Half-life25 hours
Decision GuideWhen to pick each / when to consider an alternative
Vilazodone
Consider when
- Sexual dysfunction on SSRIs/SNRIs and bupropion contraindicated — 5-HT1A partial agonism showed no CSFQ difference from placebo vs paroxetine's significant worsening
- Weight-neutral antidepressant needed — only 1–2% weight gain vs mirtazapine (~0.87 kg) or paroxetine (long-term gain)
- Minimal CYP perpetrator interactions required — does not inhibit CYP1A2, 2C9, 2C19, 2D6, or 3A4
- Comorbid anxiety with SD concern — anxiolytic effect via 5-HT1A partial agonism without bupropion's potential anxiety worsening
- +1 more
Consider an alternative when
- GI sensitivity — diarrhea 26–29% vs 10% placebo and nausea 22–24% vs 7%; worse GI burden than most SSRIs
- Food intake unreliable — must take with food; bioavailability drops ~50% fasting
- Slow titration is impractical — mandatory 7-day steps (10→20→40 mg); clinically slower than most SSRIs
- On strong CYP3A4 inhibitor — dose cap 20 mg with ketoconazole/clarithromycin; strong inducers may require up to 80 mg
- +1 more
Efficacy & Acceptability (1 axes)— NMA efficacy & discontinuation data (not side effects)
| Axis | Vilazodone |
|---|---|
| 📊 Efficacy (response rates) | |
MDDEfficacy | |
| Axis | Vilazodone SPARI |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Seizure risk | |
| Metabolic | |
Weight loss | |
Metabolic (glucose / lipids) | |
| Autonomic | |
Sweating | |
Angle-closure glaucoma | |
| Cardiac | |
QTc prolongation | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Electrolytes | |
Hyponatremia / SIADH | |
| Sexual | |
Sexual dysfunction | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
Serotonin syndrome risk | |
CYP interactions / DDI profile | |
| Safety | |
Bleeding risk | |